Leaflet TREVACLYN 1000mg / 20mg modified release tablets
- Product code:
- W53301012
- Quantity:
- 196
- Indicated for:
- dyslipidemia
- Route of administration:
- oral
- Substance:
- nicotinic acid + laropiprant (lipid-lowering agents)
- ATC
- C10AD52 — Cardiovascular system | Lipid modifying agents | Lipid modifying agents, plain | Nicotinic acid and derivatives
The combination of nicotinic acid and laropiprant is used to treat dyslipidemia, particularly to lower LDL cholesterol and triglycerides and increase HDL cholesterol. Laropiprant helps reduce the flushing side effect caused by nicotinic acid.
This combination is indicated for patients at high risk of cardiovascular diseases, especially when other treatments are not tolerated or effective. It is available in oral tablet form.
Side effects may include nausea, stomach discomfort, itching, or dizziness. Skin flushing is significantly reduced due to the presence of laropiprant.
Patients should inform their doctor about any liver conditions or other health issues before use. Monitoring liver function is recommended during treatment.
This combination is indicated for patients at high risk of cardiovascular diseases, especially when other treatments are not tolerated or effective. It is available in oral tablet form.
Side effects may include nausea, stomach discomfort, itching, or dizziness. Skin flushing is significantly reduced due to the presence of laropiprant.
Patients should inform their doctor about any liver conditions or other health issues before use. Monitoring liver function is recommended during treatment.
General data about TREVACLYN 1000mg / 20mg
- Substance:
- nicotinic acid + laropiprant
- Date of latest medicines list:
- 01-07-2013
- Product code:
- W53301012
- Concentration:
- 1000mg / 20mg
- Pharmaceutical form:
- modified release tablets
- Quantity:
- 196
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.